Floatz logo

Polyiclc

Adult Brain Glioblastoma

University Hospital, GenevaPhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Adult Brain Glioblastoma cohort.

Asset / SponsorPhaseRating
CARMUSTINE
Leland Metheny
Phase 2CCC
Fuzuloparib
National Cancer Institute (NCI)
Phase 2CCC
Zeprumetostat
National Cancer Institute (NCI)
Phase 2CCC
trc102
National Cancer Institute (NCI)
Phase 2CCC
Imiquimod
Stemline Therapeutics, Inc.
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Polyiclc is also rated in:

Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
B
Indicative ·
63 / 100
View asset →
melanomaDormant
B
Indicative ·
63 / 100
View asset →
ocular melanomaDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →